WO2026099374 - C1Q AS TARGET TO TREAT FATIGUE
National phase entry is expected:
Publication Number
WO/2026/099374
Publication Date
15.05.2026
International Application No.
PCT/EP2025/082167
International Filing Date
06.11.2025
Title **
[English]
C1Q AS TARGET TO TREAT FATIGUE
[French]
C1Q COMME CIBLE POUR TRAITER LA FATIGUE
Applicants **
UNIVERSITEIT GENT
VIB VZW
Inventors
LAUKENS, Debby
LERNOUT, Hannah
VANDENBROUCKE, Roosmarijn
Priority Data
24211518.6
07.11.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1872 | |
| EPO | Filing, Examination, Granting | 8126 | |
| Japan | Filing, Examination, Granting | 1836 | |
| South Korea | Filing, Examination, Granting | 1360 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
17,934
Contact Us
Abstract[English]
The present invention relates to compounds which are capable to bind the complement component 1, subcomponent q (C1q) and to inhibit its biological activity. More in particular, the present invention discloses the usage of said compounds to prevent or treat fatigue as comorbidity in autoimmune disease.[French]
La présente invention concerne des composés qui sont capables de se lier au composant 1 du complément, sous-composant q (C1q) et d'inhiber son activité biologique. Plus particulièrement, la présente invention divulgue l'utilisation desdits composés pour prévenir ou traiter la fatigue en tant que comorbidité dans les maladies auto-immunes.